Table 1.
Patient Characteristics
| Attribute | n | Median (range) or n (%) |
|---|---|---|
| Baseline characteristics | ||
| Female sex | 20 | 8 (40) |
| Age at admission, y | 20 | 59 (29-85) |
| Race | 20 | |
| White | 17 (85) | |
| Black or African American | 2 (10) | |
| Other | 1 (5) | |
| Hispanic or Latino ethnicity | 20 | 4 (20) |
| Body mass index, kg/m2 | 20 | 31.1 (21.6-52.4) |
| Type of hyperglycemia | 20 | |
| Type 2 DM—oral/SQ medication, no insulin | 7 (35) | |
| Type 2 DM—MDI insulin or insulin pump | 6 (30) | |
| Before admission medication-induced hyperglycemia | 1 (5) | |
| COVID-19 therapy–related hyperglycemia only | 4 (20) | |
| New DM type 2 diagnosis during current hospitalization | 2 (10) | |
| Last HbA1C (%; mmol/mol) | 16 | 7.0 (4.9-11.9); 53 (30-107) |
| Post-CGM placement information | ||
| Insulin administered while CGM was active | 20 | |
| SQ insulin only | 15 (75) | |
| Both IV and SQ insulin | 5 (25) | |
| No. of times SQ insulin was dosed based on CGM values | 20 | 8 (1-39) |
| No. of times CGM value was not documented in EPIC while SQ insulin was dosed based on CGM value | 20 | 1 (0-6) |
| Medication(s) received for treatment of COVID-19 | 20 | |
| Remdesivir | 19 (95) | |
| Dexamethasone | 19 (95) | |
| Convalescent plasma | 11 (55) | |
| Tocilizumab | 8 (40) | |
| Research trial—camostat vs placebo | 1 (5) | |
| No. of CGM calibrations on medical floors and ICU | 20 | 2.5 (0-25) |
| No. of CGM calibrations on medical floors | 20 | 2.5 (0-25) |
| No. of CGM calibrations in ICU | 6 | 1 (0-2) |
Abbreviations: CGM = continuous glucose monitor; DM = diabetes mellitus; MDI = multiple daily injections; ICU = intensive care unit; IV = intravenous; SQ = subcutaneous.